ALBANY, N.Y. (NEWS10) – The New York Attorney General’s Office announced it is launching an antitrust investigation into Mylan Pharmaceuticals Inc., the maker of EpiPens.
According to the office, Mylan pharmaceuticals may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems.
Mylan’s EpiPen is a device and drug used when an individual suffers a severe allergic reaction, which could otherwise lead to death, in the U.S. market.
Attorney General Eric Schneiderman issued this statement:
“No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices. If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable. Allergy sufferers have enough concerns to worry about—the availability of life-saving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation.”